How do you decide on adjuvant therapy in a patient with a Stage IA uterine carcinosarcoma without any myometrial invasion?
The NCCN recommends either systemic therapy + brachytherapy or pelvic RT + brachy or brachy alone or observation. How do you decide among these options? Does your recommendation change if there is invasion but < 50%?
Answer from: Radiation Oncologist at Community Practice
There is no good prospective study. Our approach, based on outcome and retrospective data (including NCDB), is brachy plus chemo. https://www.ncbi.nlm.nih.gov/pubmed/30170976This is paper I was referring to. With all the caveats of NCDB studies, it givess some objective information where prospe...
Sign in or Register to read more